On behalf of Hanmi Pharmaceuticals, I express our respect to World Korean Medical Organization (WMKO), who has played pivotal roles for Korean Healthcare Professionals worldwide who have endeavored for global health and happiness, and sincerely congratulate the first publication of the World Korean Medical Journal (WKMJ) which would greatly contribute in sharing and expanding WMKO’s activities. Also, we praise Chul-Soo Hyun, the President of WKMO, and his leadership team for making such progress.

 

Hanmi, as one of the leading Korean pharmaceuticals, has always strived to be a global company through R&D. As a result, we have developed innovative novel drugs in Oncology and Biologics, over ten of which are currently under multinational clinical trials in the US and Europe.

 

In addition to innovative novel drugs, Hanmi has developed a great number of Incrementally Modified Drugs (IMD) and Fixed-Dose Combination (FDC) drugs, entering global markets by collaboration with multinational companies such as Merck, Sanofi and GSK. Hanmi’s “ESOMEPRAZOLE STRONTIUM Delayed Release Capsule 49.3 mg”, a pharmaceutical alternative to NEXIUM® capsule 40 mg for a more affordable treatment option for gastroesophageal reflux disease (GERD) in adult patients, was launched in the US market in December 2013. Esomeprazole strontium is currently marketed in the US by Hanmi’s US partner, Amneal Pharmaceuticals.

 

All such Hanmi’s R&D activities and global market expansions have been supported by Korean Healthcare Professionals worldwide. With the first publication of WKMJ as a momentum, we wish all members of WKMO collaborate closely each other and support Korean pharmaceuticals in entering global markets. Hanmi promises to do our best efforts to contribute to the activities of WKMO in the future.

 

May the Year of the Blue Horse bring all WKMO members health, happiness, and prosperity.

Thank you.

 

Gwan Sun Lee, PhD

President & CEO
Hanmi Pharm. Co., Ltd.